Ichnos Glenmark Innovation to present phase 1 study data on Trispecific Antibody ISB 2001 at ASH…
Early results show promising response rates and safety profile for ISB 2001 in relapsed/refractory multiple myeloma patients
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.